Search
Vatalanib
go.drugbank.com/drugs/DB04879InvestigationalVatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. … Vatalanib is under investigation for the treatment of solid tumors.
Finotonlimab
go.drugbank.com/drugs/DB18859InvestigationalFinotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016. … Dotatate gallium (Ga-68) is a somatostatin-2 receptor analog which is radiolabeled with gallium 68 as a positron-emitting radioisotope.
Synonyms: (68)Ga-DOTA-TATE, Ga 68 DOTATOCTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalTezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class. … Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat [L53533 … Sebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293].
Categories: Drugs Used in Hereditary AngioedemaSynonyms: 1H-Pyrazole-4-carboxamide, N-[(3-fluoro-4-methoxy-2-pyridinyl)methyl]-3-methoxymethyl)-1-[[4-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]methyl]-, N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1(2H)-yl)methyl]phenyl}methyl)-1H-pyrazol-4-carboxamideEtranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … [L44181] Hemophilia B is the second most common type of hemophilia,[L44181] with a prevalence of approximately one in 40,000.
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … The drug is only effective in patients with a susceptible IDH1 mutation.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFosinopril
go.drugbank.com/drugs/DB00492ApprovedInvestigationalIt is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). … Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals
Categories: Agents Acting on the Renin-Angiotensin SystemProducts: FOSINOPRIL Na, Lin-fosinoprilLercanidipine
go.drugbank.com/drugs/DB00528ApprovedInvestigationalWithdrawnLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Mixtures: ENALAPRIL/LERCA AL 10/10MG, ENALAPRIL/LERCA AL 10/10MGCategories: Angiotensin II receptor blockers (ARBs) and calcium channel blockers